慢性炎症性脱髄性多発根ニューロパチー（CIDP）

DOI
  • 飯島 正博
    名古屋大学大学院神経内科・難治性神経疾患治療学

書誌事項

タイトル別名
  • Chronic inflammatory demyelinating polyradiculoneuropathy

この論文をさがす

抄録

<p>First–line therapies (intravenous immunoglobulin, corticosteroids, and plasmapheresis) of CIDP are already established, but cannot be excessive expectations to the effectiveness of the second–line such as immunosuppressant. Usefulness of the maintenance therapy represented by continuous half–dose IVIg or subcutaneous immunoglobulin (SCIg) has been widely recognized. However, the proper amount of immunoglobulin for maintenance therapy is not clear. In addition, the proper period to begin the withdrawal from the maintenance therapy is not clarified yet. We should find the biomarkers to distinguish the patients who need the maintenance therapy from the “benign” others with monophasic course.</p><p>From the pathogenesis of CIDP, autoantibodies that target the molecules (eg. CNTN1, NF155) near the nodes of Ranvier are detected in at least a few percent of whole CIDP patients. These autoantibodies are unique since the autoantibody–positive patients show the similar phenotype including IVIg poor–responsiveness. The usefulness of therapeutics that could remove the antibody such as plasmapheresis, rituximab, and autologous haematopoietic stem cell transplantation (AHSCT) could be expected as a promising treatment. Finally, we should carefully consider those autoantibodies when setting up future clinical trials for CIDP.</p>

収録刊行物

  • 神経治療学

    神経治療学 33 (2), 168-171, 2016

    日本神経治療学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ